Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
In 2013 a multidisciplinary expert group of international leaders in emergency medicine and acute heart failure (AHF) was convened in order to establish an AHF Academy.
The aim was to provide high quality teaching and educational materials for all involved in the management of AHF in the emergency setting, with a view to increasing understanding of this critical condition as well as potentially improving patient outcomes.
ACCA had no official involvement in the development of content for the AHF Academy managed independently by CircleScience and supported by Novartis. ACCA has subsequently evaluated the content of the interactive case studies and considers the scientific relevance of these cases to be high and appropriate for dissemination to the multi-professional team via this platform.
Any questions on these cases should be addressed to email@example.com
These case studies are intended for non-promotional, illustrative and training purposes only and are accurate at the time of release.They should not replace clinical judgement. The cases may include information on investigational uses of compounds/drugs that have not been approved by regulatory authorities.
As laboratory test results vary depending on local practice, assay type and test manufacturer, please refer to the standard reference ranges provided.
Furthermore, abnormal results are highlighted in bold text with additional information on specific test results provided in the footnotes.Each outstanding case has been created solely by an individual Academy member. Additional members of the AHF Academy then peer-reviewed each case to ensure accuracy and completeness.
Novartis Pharma AG supported the AHF Academy meetings and editorial assistance which was provided by CircleScience (an Ashfield Company, part of UDG Healthcare plc).
We believe these cases will improve the early management of AHF in the emergency care setting.
Martin Möckel, MD, PhD, FESC, FAHAFull Professor and AHF Academy co-chairCharité–Universitätsmedizin BerlinBerlin; Germany
Peter S. Pang, MD, MSc, FACEP, FAAEM, FAHA, FACCAssociate Professor and AHF Academy co-chairIndiana University School of MedicineIndianapolis, IN; USA
© 2017 European Society of Cardiology. All rights reserved